| Description |
SPL-334 is a potent and selective S-Nitrosoglutathione reductase (GSNOR) inhibitor. SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways. SPL-334 can be used in research of allergic airway inflammation[1].
|
| Related Catalog |
|
| In Vivo |
SPL-334 (0.1-1 mg/kg; 鼻内给药; 每日一次, 持续 7 天; 带有 DO11.10 CD4+ Th2 异种移植物的 BALB/c 受体小鼠) 导致过敏性气道炎症减少[1] . Animal Model: BALB/c recipient mice with DO11.10 CD4+ Th2 xenograft[1] Dosage: 0.1 or 1 mg/kg Administration: Intranasal administration; daily, for 7 days Result: Caused a significant reduction in the influx of lymphocytes and eosinophils into the airways and the level of EPO in the BALF. Reduced the number of OVA-specific T cells and eosinophils during allergic airway inflammation. Reduced in peribronchial inflammation and mucus secretion during airway inflammation.
|
| References |
[1]. Ferrini ME, et, al. S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity. PLoS One. 2013 Jul 25;8(7):e70351.
|
